微芯生物
(688321)
| 流通市值：127.73亿 | | | 总市值：138.73亿 |
| 流通股本：4.08亿 | | | 总股本：4.43亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 257,038,676.31 | 910,061,840.72 | 674,157,709.09 | 406,598,517.7 |
| 营业收入 | 257,038,676.31 | 910,061,840.72 | 674,157,709.09 | 406,598,517.7 |
| 二、营业总成本 | 224,552,523.96 | 846,023,589.62 | 597,523,641.23 | 376,480,827.83 |
| 营业成本 | 36,503,390.46 | 117,232,405.12 | 85,688,251.86 | 53,759,265.41 |
| 税金及附加 | 3,185,062.23 | 11,157,336.67 | 8,028,334.76 | 4,608,927.33 |
| 销售费用 | 105,181,815.67 | 381,219,426.87 | 260,271,708.65 | 159,189,952.57 |
| 管理费用 | 20,782,326.96 | 93,283,627.32 | 66,069,647.05 | 44,383,799.91 |
| 研发费用 | 51,620,365.32 | 221,622,337.71 | 162,389,467.25 | 105,515,201.73 |
| 财务费用 | 7,279,563.32 | 21,508,455.93 | 15,076,231.66 | 9,023,680.88 |
| 其中:利息费用 | 8,537,357 | 35,697,501.65 | 26,934,960.53 | 17,518,130.97 |
| 其中:利息收入 | 3,002,992.24 | 17,043,959.3 | 13,439,851.74 | 9,118,579.39 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 769,502.3 | 238,945.2 | 177,698.63 | - |
| 加:投资收益 | -5,709,860.17 | -25,076,401.36 | -16,853,160.28 | -10,753,345.71 |
| 信用减值损失(新) | -1,002,530.42 | -3,179,813.34 | -1,359,013.51 | -271,353.09 |
| 其他收益 | 2,353,155.88 | 14,090,999.37 | 11,799,437.6 | 9,027,928.41 |
| 四、营业利润 | 28,896,419.94 | 50,111,980.97 | 70,399,030.3 | 28,120,919.48 |
| 加:营业外收入 | 2,601.64 | 33,698.97 | 16,680.94 | 7,823.9 |
| 减:营业外支出 | 246,692.67 | 93,229.41 | 100,950.89 | 63,106.02 |
| 五、利润总额 | 28,652,328.91 | 50,052,450.53 | 70,314,760.35 | 28,065,637.36 |
| 减:所得税费用 | 380,459.87 | -906,712.03 | -452,754.5 | -1,526,591.47 |
| 六、净利润 | 28,271,869.04 | 50,959,162.56 | 70,767,514.85 | 29,592,228.83 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 28,271,869.04 | 50,959,162.56 | 70,767,514.85 | 29,592,228.83 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 28,271,869.04 | 50,959,162.56 | 70,767,514.85 | 29,592,228.83 |
| 扣除非经常损益后的净利润 | 25,644,077.87 | 38,179,827.88 | 58,436,427.07 | 20,320,083.48 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.07 | 0.13 | 0.17 | 0.07 |
| (二)稀释每股收益 | 0.07 | 0.13 | 0.17 | 0.07 |
| 八、其他综合收益 | -673,116.67 | -972,852.61 | -516,553.25 | -209,350.4 |
| 归属于母公司股东的其他综合收益 | -673,116.67 | -972,852.61 | -516,553.25 | -209,350.4 |
| 九、综合收益总额 | 27,598,752.37 | 49,986,309.95 | 70,250,961.6 | 29,382,878.43 |
| 归属于母公司股东的综合收益总额 | 27,598,752.37 | 49,986,309.95 | 70,250,961.6 | 29,382,878.43 |
| 公告日期 | 2026-04-30 | 2026-03-31 | 2025-10-31 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |